ArticleBioactive materials2026
Bilayer tri-dermal-network hydrogel for sequential delivery of PD-168077 in multimodal diabetic wound regeneration.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic chronic wounds (DCWs) present a complex pathophysiology. Therapeutic development is hindered by two key challenges: flawed drug discovery comparisons (e.g., normal vs. DCW skin) that include systemic factors, and advanced dressings that rely on complex, difficult-to-translate designs. This study first introduces a precise Cmap screening strategy, comparing human self-healing versus non-healing DCW patient skin, to identify the dopamine D4 receptor (DRD4) agonist PD-168077 (PD) as a novel therapeutic. To overcome delivery challenges, a biomimetic dermal hydrogel (PCHMA) was fabricated from natural skin components (hyaluronic acid and collagen I/III). This system utilizes a notably facile "single formulation, dual concentrations, dual curing" matrix photopolymerization to create a bilayer-structure hydrogel with triple-crosslinking network. The resulting matrix possesses intrinsic therapeutic capabilities and provides programmed drug release via a "fast-release" layer for immediate anti-inflammation and a "slow-release" layer for sustained regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.